↓ Skip to main content

Dove Medical Press

Article Metrics

Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis

Overview of attention for article published in Therapeutics and Clinical Risk Management, March 2010
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (79th percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

patent
3 patents
wikipedia
1 Wikipedia page

Citations

dimensions_citation
48 Dimensions

Readers on

mendeley
136 Mendeley
Title
Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis
Published in
Therapeutics and Clinical Risk Management, March 2010
DOI 10.2147/tcrm.s5599
Pubmed ID
Authors

Mark Lebwohl, Jason Emer, Nora Koutruba

Abstract

The pathogenesis of psoriasis is unknown, although it is generally accepted that this chronic inflammatory skin disorder is a complex autoimmune condition similar to other T-cell mediated disorders. Psoriasis imposes a heavy burden on the lifestyle of those affected due to the psychological, arthritic, and cutaneous morbidities; thus significant research has focused on the genetic and immunologic features of psoriasis in anticipation of more targeted, efficacious, and safe therapies. Recently, CD4(+) T helper (Th) 17 cells and interleukins (IL)-12 and -23 have been important in the pathogenesis of T-cell mediated disorders such as psoriasis and has influenced the development of medications that specifically target these key immunological players. Ustekinumab is a monoclonal antibody belonging to a newly developed class of biological, anti-cytokine medications that notably targets the p40 subunit of both IL-12 and -23, both naturally occurring proteins that are important in regulating the immune system and are understood to play a role in immune-mediated inflammatory disorders. Ustekinumab's safety and efficacy has been evaluated for the treatment of moderate-to-severe plaque psoriasis in 3 phase III clinical trials, 2 placebo-controlled (PHOENIX 1 and 2), and 1 comparator-controlled (ACCEPT) study which proved advantageous in patients who were treatment-naive, previously failed other immunosuppressive medications including cyclosporine or methotrexate, were unresponsive to phototherapy, or were unable to use or tolerate other therapies. Ustekinumab has also been investigated for other indications such as psoriatic arthritis, Crohn's disease, and relapsing/remitting multiple sclerosis. We present a concise review evaluating the evidence that supports the use of ustekinumab in the treatment of plaque psoriasis and other conditions.

Mendeley readers

The data shown below were compiled from readership statistics for 136 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Colombia 1 <1%
Brazil 1 <1%
United Kingdom 1 <1%
Singapore 1 <1%
Spain 1 <1%
Greece 1 <1%
Unknown 130 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 27 20%
Student > Ph. D. Student 19 14%
Student > Master 19 14%
Student > Bachelor 16 12%
Other 14 10%
Other 19 14%
Unknown 22 16%
Readers by discipline Count As %
Medicine and Dentistry 54 40%
Agricultural and Biological Sciences 13 10%
Biochemistry, Genetics and Molecular Biology 12 9%
Pharmacology, Toxicology and Pharmaceutical Science 11 8%
Neuroscience 4 3%
Other 13 10%
Unknown 29 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 February 2019.
All research outputs
#3,487,153
of 17,356,510 outputs
Outputs from Therapeutics and Clinical Risk Management
#161
of 1,100 outputs
Outputs of similar age
#59,240
of 295,067 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#8
of 28 outputs
Altmetric has tracked 17,356,510 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,100 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.9. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 295,067 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.